Bristol Myers Squibb (BMY) Research & Development (2009 - 2026)

Bristol Myers Squibb (BMY) has reported Research & Development for 18 consecutive years, with $3.0 billion the latest figure, recorded in Q2 2026.

• On a quarterly basis, Research & Development rose 14.69% year-over-year to $3.0 billion in Q2 2026; TTM through Jun 2026 was $10.7 billion, a 3.08% increase from a year earlier, with the FY2025 full-year figure at $10.0 billion, down 10.83% from the prior year.
• Research & Development was $3.0 billion for Q2 2026 at Bristol Myers Squibb, up from $2.6 billion in the prior quarter.
• Over five years, Research & Development peaked at $3.2 billion in Q4 2024 and troughed at $2.2 billion in Q3 2023.
• A 5-year average of $2.5 billion and a median of $2.5 billion in 2022 frame the typical range for Research & Development.
• Across the five-year window, Research & Development gained 28.77% in 2024 and fell 18.96% in 2025, its largest moves.
• Over 5 years, Research & Development stood at $2.5 billion in 2022, then slipped by 1.27% to $2.5 billion in 2023, then grew by 28.77% to $3.2 billion in 2024, then slipped by 18.96% to $2.6 billion in 2025, then advanced by 14.42% to $3.0 billion in 2026.
• The last three Research & Development figures came in at $3.0 billion (Q2 2026), $2.6 billion (Q1 2026), and $2.6 billion (Q4 2025), per Business Quant data.